Entries by Maren Kühr

Faron Pharmaceuticals with Interim CFO

Finnish Faron Pharmaceuticals Ltd. announces the appointment of Yrjö Wichmann as Interim Chief Financial Officer. He took over the role in mid-April because his predecessor James O’Brien is leaving Faron to take up another job opportunity outside the company.

Biology as Software

At a recent event researcher and founder of Bit.bio, Prof. Mark Kotter, Babraham Research Campus in Cambridge/UK, was asked what healthcare looks like in 2050. He gave a twofold answer, that it will be driven by data, but also will be personalised. Mark Kotter elaborates here in more detail what is needed to unlock a healthcare of tomorrow.

SMEs suffer from CTIS

Born with the aim of harmonising the application, evaluation, and supervision process of clinical trials conducted in EU countries, there is much room for improvement for the Clinical Trial Information System CTIS, particularly with regard to SMEs and translational researchers.

14th European Biotechnology Science & Industry Guide 2024

The 14th edition of the European Biotechnology Science & Industry Guide is showcasing brilliant science and excellent business from companies, universities, research institutes, and expert support providers. In addition to the detailed portraits on approx. 164 colored pages, the guide features a report about sustainability and the biologisation of industrial production. Readers will discover many success stories and current trends in the European biotech industry.

You can browse through the current issue here or order your personal print copy on biospheria.shop.

Are there bright times for biotech IPOs ahead?

Despite the recent stock market rally and declining volatility, IPOs are rather rare in many industrialised countries –not least for seasonal reasons. The main reason for this, however, is the aggressive monetary policy of the central banks, with more than ten interest rate hikes in both Europe and the US. 

Meeting rising demand

Radiopharmaceutical Therapy (RPT) is offering several advantages over existing therapeutic strategies. The highly sought-after therapeutics require a sophisticated supply chain, as radioisotopes have short half-lives and must be delivered to patients with extreme speed and efficiency. ITM rises to this challenge as one of the largest global providers and developers of medical radioisotopes for this novel therapy.

Cultivated meat debate clouded by misinformation

As cultivated meat moves closer to commercialisation, we are seeing a worrying trend of misinformation entering the public debate. This food can play a vital role in ensuring Europe’s food system is fit for the future – helping satisfy the growing demand for meat while boosting food security – but political opposition has mounted, with the Italian government taking the controversial step of banning cultivated meat.

Experts in microbial technology

The world of microbial product manufacturing is a complex landscape, ­driven by a diverse range of molecule formats and manufacturing processes. At the forefront of this specialty market is Boehringer Ingelheim Vienna, one global leader in biopharmaceutical development and manufacturing.